<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02569892</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-33991</org_study_id>
    <nct_id>NCT02569892</nct_id>
  </id_info>
  <brief_title>Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration</brief_title>
  <official_title>Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bascom Palmer Eye Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled study of non-damaging photothermal macular grid laser versus&#xD;
      sham laser therapy in patients with dry age-related macular degeneration (AMD) and large&#xD;
      high-risk drusen. The goal of the study is to determine if this treatment will reduce macular&#xD;
      drusen volume and also whether this might improve visual acuity or reduce the risk of&#xD;
      conversion to advanced age-related macular degeneration defined as development of choroidal&#xD;
      neovascularization or geographic atrophy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">January 25, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Macular Drusen Volume</measure>
    <time_frame>baseline, 6, 12, and 24 months</time_frame>
    <description>Mean change in macular drusen volume as measured on high-resolution spectral domain ocular coherence tomography (SD-OCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity</measure>
    <time_frame>baseline, 6, 12, and 24 months</time_frame>
    <description>Mean change in best-corrected visual acuity as measured using early treatment diabetic retinopathy study (ETDRS) chart - average number of letters seen on chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Geographic Atrophy (GA) or Choroidal Neovascularization (CNV)</measure>
    <time_frame>2 years</time_frame>
    <description>Count of eyes that develop geographic atrophy or choroidal neovascularization by 24 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Macular Degeneration</condition>
  <condition>Retinal Drusen</condition>
  <arm_group>
    <arm_group_label>Laser Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive treatment with sub-threshold macular laser photocoagulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Laser Arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants receive sham treatment with sub-threshold macular laser photocoagulation (with power setting at zero)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pascal Retinal Laser Photocoagulator</intervention_name>
    <description>Sub-threshold macular laser treatment with Pascal laser Endpoint Management System</description>
    <arm_group_label>Laser Arm</arm_group_label>
    <arm_group_label>Sham Laser Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Older than 60 years of age.&#xD;
&#xD;
          2. Male or female patients with nonexudative AMD with a drusen volume of of at least&#xD;
             0.03mm3 in the central 3mm circle&#xD;
&#xD;
          3. Adequate pupil dilatation and clear media to perform colour, red-free imaging and&#xD;
             fundus fluorescein angiography, fundus autofluorescence imaging and OCT.&#xD;
&#xD;
          4. Able to give an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of signs of advanced AMD, such as CNV, haemorrhages or macular atrophy based&#xD;
             on OCT and fundus autofluorescence photography (FAF).&#xD;
&#xD;
          2. Previous macular laser treatment.&#xD;
&#xD;
          3. Any previous ocular condition that may be associated with a risk of developing macular&#xD;
             oedema.&#xD;
&#xD;
          4. Vitreomacular traction determined clinically and /or by OCT, which in the opinion of&#xD;
             the investigator, contributes to the macular oedema (associated or causing a&#xD;
             detachment of the fovea).&#xD;
&#xD;
          5. Presence of other macular disease such as epiretinal membrane, macular telangiectasia.&#xD;
&#xD;
          6. Important known allergies to sodium fluorescein dye used in angiography.&#xD;
&#xD;
          7. Ocular or periocular infections.&#xD;
&#xD;
          8. Planned intra-ocular surgery within one year.&#xD;
&#xD;
          9. Patient is unavailable for follow-up visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Sanislo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <results_first_submitted>March 9, 2021</results_first_submitted>
  <results_first_submitted_qc>April 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2021</results_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Steven R. Sanislo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Retinal Drusen</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT02569892/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from January 2016 until May 2018, at which time interim analysis revealed futility.</recruitment_details>
      <pre_assignment_details>19 participants signed informed consent; 2 participants failed screening, and 17 participants started the study. Participants may have contributed one or both eyes to the study. If both eyes were enrolled the first eye would be randomly assigned to treatment or sham, and the fellow eye would be assigned to the opposite treatment arm. Participants who contributed more than one eye are counted in more than one reporting group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sub-threshold Macular Laser Photocoagulation</title>
          <description>Participants that receive treatment with sub-threshold macular laser photocoagulation</description>
        </group>
        <group group_id="P2">
          <title>Sham Laser</title>
          <description>Participants that receive sham treatment with sub-threshold macular laser photocoagulation (with power setting at zero)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Participants receive sub-threshold macular laser photocoagulation and/or sham treatment with power setting at zero</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Macular Drusen Volume</title>
        <description>Mean change in macular drusen volume as measured on high-resolution spectral domain ocular coherence tomography (SD-OCT)</description>
        <time_frame>baseline, 6, 12, and 24 months</time_frame>
        <population>Participants who contributed more than one eye are counted in more than one reporting group. Data for the participant who did not complete the study are included using the Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sub-threshold Macular Laser Photocoagulation</title>
            <description>Participants that receive treatment with sub-threshold macular laser photocoagulation</description>
          </group>
          <group group_id="O2">
            <title>Sham Laser</title>
            <description>Participants that receive sham treatment with sub-threshold macular laser photocoagulation (with power setting at zero)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Macular Drusen Volume</title>
          <description>Mean change in macular drusen volume as measured on high-resolution spectral domain ocular coherence tomography (SD-OCT)</description>
          <population>Participants who contributed more than one eye are counted in more than one reporting group. Data for the participant who did not complete the study are included using the Last Observation Carried Forward (LOCF) method.</population>
          <units>mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.05" upper_limit="0.14"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.07" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="6.04" upper_limit="33.30"/>
                    <measurement group_id="O2" value="9.0" lower_limit="-55.50" upper_limit="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" lower_limit="25.00" upper_limit="55.01"/>
                    <measurement group_id="O2" value="27.2" lower_limit="-85.70" upper_limit="46.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 month change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="34.75" upper_limit="135.00"/>
                    <measurement group_id="O2" value="-4.5" lower_limit="-85.70" upper_limit="81.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Acuity</title>
        <description>Mean change in best-corrected visual acuity as measured using early treatment diabetic retinopathy study (ETDRS) chart - average number of letters seen on chart</description>
        <time_frame>baseline, 6, 12, and 24 months</time_frame>
        <population>Participants who contributed more than one eye are counted in more than one reporting group. Data for the participant who did not complete the study are included using the Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sub-threshold Macular Laser Photocoagulation</title>
            <description>Participants that receive treatment with sub-threshold macular laser photocoagulation</description>
          </group>
          <group group_id="O2">
            <title>Sham Laser</title>
            <description>Participants that receive sham treatment with sub-threshold macular laser photocoagulation (with power setting at zero)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity</title>
          <description>Mean change in best-corrected visual acuity as measured using early treatment diabetic retinopathy study (ETDRS) chart - average number of letters seen on chart</description>
          <population>Participants who contributed more than one eye are counted in more than one reporting group. Data for the participant who did not complete the study are included using the Last Observation Carried Forward (LOCF) method.</population>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline vision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7" spread="8.60"/>
                    <measurement group_id="O2" value="79.4" spread="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="4.24"/>
                    <measurement group_id="O2" value="-3.4" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="324"/>
                    <measurement group_id="O2" value="-0.9" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 month change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="6.10"/>
                    <measurement group_id="O2" value="-6.3" spread="6.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Geographic Atrophy (GA) or Choroidal Neovascularization (CNV)</title>
        <description>Count of eyes that develop geographic atrophy or choroidal neovascularization by 24 months.</description>
        <time_frame>2 years</time_frame>
        <population>Participants who contributed more than one eye are counted in more than one reporting group. Data for the participant who did not complete the study are included using the Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sub-threshold Macular Laser Photocoagulation</title>
            <description>Participants that receive treatment with sub-threshold macular laser photocoagulation</description>
          </group>
          <group group_id="O2">
            <title>Sham Laser</title>
            <description>Participants that receive sham treatment with sub-threshold macular laser photocoagulation (with power setting at zero)</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Geographic Atrophy (GA) or Choroidal Neovascularization (CNV)</title>
          <description>Count of eyes that develop geographic atrophy or choroidal neovascularization by 24 months.</description>
          <population>Participants who contributed more than one eye are counted in more than one reporting group. Data for the participant who did not complete the study are included using the Last Observation Carried Forward (LOCF) method.</population>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>Per protocol, only adverse events related to treatment were collected. Participants who contributed more than one eye are counted in more than one reporting group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sub-threshold Macular Laser Photocoagulation</title>
          <description>Participants that receive treatment with sub-threshold macular laser photocoagulation</description>
        </group>
        <group group_id="E2">
          <title>Sham Laser</title>
          <description>Participants that receive sham treatment with sub-threshold macular laser photocoagulation (with power setting at zero)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>mild supra-threshold laser burns</sub_title>
                <description>Laser burns in this study were to be sub-threshold (non-visible).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study did not meet enrollment goal of 60 study eyes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Steven Sanislo, MD</name_or_title>
      <organization>Stanford University School of Medicine</organization>
      <phone>650-723-6995</phone>
      <email>ssanislo@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

